TAK Stock Analysis: Buy, Sell, or Hold?
TAK - Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
$16.77
0.82 (5.14%)
▲
5d:
+7.16%
30d:
+10.47%
90d:
-10.66%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 30, 2026
25d
Get Alerted When TAK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TAK shows positive signals but monitor for confirmation. Market pricing in 1.2% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: TAK shows positive signals but monitor for confirmation. Market pricing in 1.2% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$36.99
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$22.97
27.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 0.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TAK is currently trading at $16.77, which is considered extended relative to its 30-day fair value range of $15.41 to $16.09. From a valuation perspective, the stock is trading at a discount (Forward PE: 0.2) compared to its historical average (0.2). At these levels, the market is pricing in 1.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TAK is in a strong downtrend. The price is approaching resistance at $16.77. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: TAK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.95 (+24.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TAK is in a strong downtrend. The price is approaching resistance at $16.77. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: TAK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.95 (+24.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$15.41 -
$16.09
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
71.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.1%)
- BULLISH: Trading 24.9% below Wall St target ($20.95)
- BULLISH: Market expects only 1.2% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$15.41 -
$16.09
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$15.39
Resistance Level
$16.77
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
0.18
Wall Street Target
$20.95
(+24.9%)
Revenue Growth (YoY)
3.9%
Earnings Growth (YoY)
330.2%
Profit Margin
-3.4%
Valuation Premium vs History
+1.2% premium
PE vs Historical
0.2 vs 0.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.2%
(market-implied from PE analysis)
1-Year Target
$16.97
(+1%)
2-Year Target
$17.17
(+2%)
3-Year Target
$17.38
(+4%)
3-Yr Target (if PE normalizes)
(PE: 0→0)
$19.69
(+17%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 93.0%)
$6981.89
(+41533%)
Base:
(SPY PE: 0.2, Growth: 93.0%)
$56.60
(+238%)
Bear:
(PE: 0.2, Growth: 93.0%)
$48.11
(+187%)
Share & Embed Analysis
Last updated: July 04, 2026 3:46 AM ET
Data refreshes hourly during market hours. Next update: 4:46 AM
Data refreshes hourly during market hours. Next update: 4:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TAK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 62 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 63 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 61 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 54 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 60 HOLD |
